- Home
- ENZ vs LSB Comparison
ENZ vs LSB Comparison
Compare ENZ & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENZ
- LSB
- Stock Information
- Founded
- ENZ 1976
- LSB 2002
- Country
- ENZ United States
- LSB China
- Employees
- ENZ N/A
- LSB N/A
- Industry
- ENZ Medical Specialities
- LSB
- Sector
- ENZ Health Care
- LSB
- Exchange
- ENZ Nasdaq
- LSB NYSE
- Market Cap
- ENZ 34.2M
- LSB 32.2M
- IPO Year
- ENZ N/A
- LSB N/A
- Fundamental
- Price
- ENZ $0.31
- LSB $1.38
- Analyst Decision
- ENZ
- LSB
- Analyst Count
- ENZ 0
- LSB 0
- Target Price
- ENZ N/A
- LSB N/A
- AVG Volume (30 Days)
- ENZ 625.0K
- LSB 34.3K
- Earning Date
- ENZ 06-12-2025
- LSB 12-19-2024
- Dividend Yield
- ENZ 31.59%
- LSB N/A
- EPS Growth
- ENZ N/A
- LSB N/A
- EPS
- ENZ N/A
- LSB N/A
- Revenue
- ENZ $29,094,000.00
- LSB $79,415,311.00
- Revenue This Year
- ENZ N/A
- LSB $39.33
- Revenue Next Year
- ENZ N/A
- LSB $75.61
- P/E Ratio
- ENZ N/A
- LSB N/A
- Revenue Growth
- ENZ N/A
- LSB N/A
- 52 Week Low
- ENZ $0.25
- LSB $1.50
- 52 Week High
- ENZ $1.27
- LSB $11.20
- Technical
- Relative Strength Index (RSI)
- ENZ 39.61
- LSB 28.40
- Support Level
- ENZ $0.26
- LSB $1.50
- Resistance Level
- ENZ $0.42
- LSB $1.79
- Average True Range (ATR)
- ENZ 0.07
- LSB 0.23
- MACD
- ENZ 0.01
- LSB -0.08
- Stochastic Oscillator
- ENZ 35.29
- LSB 5.80
About ENZ Enzo Biochem Inc. ($0.01 Par Value)
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. The company has one reportable segment, Products, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.